Literature DB >> 23147657

Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma.

Roberta W C Pang, Ronnie T P Poon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147657     DOI： 10.1038/nrgastro.2012.208

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

Authors:  Junliang Fu; Dongping Xu; Zhenwen Liu; Ming Shi; Ping Zhao; Baoyun Fu; Zheng Zhang; Huiyin Yang; Hui Zhang; Chunbao Zhou; Jinxia Yao; Lei Jin; Huifen Wang; Yongping Yang; Yang-Xing Fu; Fu-Sheng Wang
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

2.  Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients.

Authors:  Jia Zhou; Tong Ding; Weidong Pan; Ling-Yan Zhu; Lian Li; Limin Zheng
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

3.  The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.

Authors:  Koji Hashimoto; Yasuharu Ikeda; Daisuke Korenaga; Kazuo Tanoue; Motoharu Hamatake; Katsumi Kawasaki; Terutoshi Yamaoka; Yasue Iwatani; Kohei Akazawa; Kenji Takenaka
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

4.  Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.

Authors:  Ho Jung An; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Myung Ah Lee; Young Kyoung You; Dong Goo Kim; Eun Sun Jung
Journal:  Liver Transpl       Date:  2012-12       Impact factor: 5.799

5.  Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.

Authors:  Tim F Greten; Lars A Ormandy; Annika Fikuart; Bastian Höchst; Sylvana Henschen; Monique Hörning; Michael P Manns; Firouzeh Korangy
Journal:  J Immunother       Date:  2010 Feb-Mar       Impact factor: 4.456

6.  Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma.

Authors:  Jeong Won Jang; Byong Sun Oh; Jung Hyun Kwon; Chan Ran You; Kyu Won Chung; Chul Seung Kay; Hyun Suk Jung
Journal:  Cytokine       Date:  2012-08-18       Impact factor: 3.861

7.  Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma.

Authors:  Junliang Fu; Zheng Zhang; Lin Zhou; Zhaorui Qi; Shaojun Xing; Jiyun Lv; Jianfei Shi; Baoyun Fu; Zhenwen Liu; Ji-Yuan Zhang; Lei Jin; Yulai Zhao; George K K Lau; Jingmin Zhao; Fu-Sheng Wang
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

8.  Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

Authors:  Wolfgang Sieghart; Matthias Pinter; Florian Hucke; Ivo Graziadei; Maximilian Schöniger-Hekele; Christian Müller; Wolfgang Vogel; Michael Trauner; Markus Peck-Radosavljevic
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

9.  Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.

Authors:  Alexander Pedroza-Gonzalez; Cornelis Verhoef; Jan N M Ijzermans; Maikel P Peppelenbosch; Jaap Kwekkeboom; Joanne Verheij; Harry L A Janssen; Dave Sprengers
Journal:  Hepatology       Date:  2012-12-04       Impact factor: 17.425

Review 10.  Biology of hepatocellular carcinoma.

Authors:  Roberta W C Pang; Jae Won Joh; Philip J Johnson; Morito Monden; Timothy M Pawlik; Ronnie T P Poon
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344
  10 in total
  4 in total

1.  The High-Sensitivity C-Reactive Protein/Albumin Ratio Predicts Long-Term Oncologic Outcomes after Curative Resection for Hepatocellular Carcinoma.

Authors:  Tak Kyu Oh; Young-Rok Choi; Jai Young Cho; Yoo-Suk Yoon; Ho-Seong Han; In Sun Park; Jung-Hee Ryu
Journal:  J Clin Med       Date:  2018-06-07       Impact factor: 4.241

2.  Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy.

Authors:  Zilong Zhang; Yuxin Liang; Deyuan Zhong; Zonglin Dai; Jin Shang; Chunyou Lai; Haibo Zou; Yutong Yao; Tianhang Feng; Xiaolun Huang
Journal:  J Clin Lab Anal       Date:  2022-03-21       Impact factor: 3.124

3.  Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China.

Authors:  Rui Liao; Yi-Peng Fu; Ting Wang; Zhi-Gang Deng; De-Wei Li; Jia Fan; Jian Zhou; Gen-Sheng Feng; Shuang-Jian Qiu; Cheng-You Du
Journal:  Oncotarget       Date:  2017-01-03

Review 4.  Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Nanping Lin; Jingrong Li; Qiao Ke; Lei Wang; Yingping Cao; Jingfeng Liu
Journal:  Dis Markers       Date:  2020-09-02       Impact factor: 3.434
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.